CS
ADMA icon

Credit Suisse’s ADMA Biologics ADMA Stock Holding History

Credit Suisse’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$2.09M Sell
316,693
-22,957
-7% -$125K ﹤0.01% 1831
2023
Q4 		$1.54M Sell
339,650
-509
-0.1% -$1.88K ﹤0.01% 2058
2023
Q3 		$1.22M Sell
340,159
-59,029
-15% -$227K ﹤0.01% 2161
2023
Q2 		$1.47M Buy
399,188
+165,775
+71% +$614K ﹤0.01% 2129
2023
Q1 		$773K Buy
233,413
+10,347
+5% +$35.8K ﹤0.01% 2476
2022
Q4 		$865K Buy
223,066
+222,001
+20,845% +$685K ﹤0.01% 2443
2022
Q3 		$3K Buy
1,065
+974
+1,070% +$2.34K ﹤0.01% 3662
2022
Q2 		$0 Buy
+91
New +$179 ﹤0.01% 3881
2021
Q4 		– Sell
-35,000
Closed -$40K – 4474
2021
Q3 		$40K Buy
+35,000
New +$49K ﹤0.01% 4354
2021
Q2 		– Sell
-18,328
Closed -$32K – 4435
2021
Q1 		$32K Buy
18,328
+3,694
+25% +$8.45K ﹤0.01% 4245
2020
Q4 		$28K Buy
+14,634
New +$30.8K ﹤0.01% 4288
2019
Q4 		– Sell
-12,162
Closed -$54K – 4137
2019
Q3 		$54K Buy
+12,162
New +$50.8K ﹤0.01% 4026

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Credit Suisse's ADMA Position: Q1 2024 in Review

Credit Suisse reduced its ADMA Biologics (ADMA) stake by 6.8% in Q1 2024, selling an estimated $125K and leaving 316,693 shares worth $2.09M. The position accounts for ﹤0.01% of the portfolio, ranked #1831.

Credit Suisse first reported a position in ADMA in Q3 2019 and has held it in 12 quarters since. 214 funds tracked by Wall St. Rank hold ADMA as of Q1 2024.

  • Credit Suisse held 316,693 shares of ADMA Biologics worth $2.09M as of Q1 2024.
  • Credit Suisse sold 22,957 ADMA Biologics shares in Q1 2024, an estimated $125K.
  • ADMA Biologics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1831 holding.
  • Credit Suisse first reported a position in ADMA Biologics in Q3 2019 and has held it in 12 quarters since.
  • 214 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.